Principal investigator Carlos Tirado, MD, a Texas-based addiction medicine specialist and chief medical officer of research site CARMAhealth Management, has inked a collaborative deal to study an investigational, noninvasive device developed by Dallas-based Spark Biomedical Inc. As the opioid crisis rages on, some liken the patient’s perspective on withdrawal to “the vampire’s view on sunlight.”
CARMAhealth is a Texas-based addiction medicine-focused provider and research center. It is an integrated behavioral health and primary care organization, the Editor of Addiction Professional, Gary Enos, reports. They offer medical support in two treatment facilities found in Austin and South Florida called “Recovery Unplugged.” As touted on their website, they offer an array of substance abuse treatment services.
The Study and Target
It is hoped that data generated from the 40 participant study will lead to Food and Drug Administration (FDA) approval of the “Phoenix,” the Spark Biomedical device—by Q3 2020. The goal of the study, where the Phoenix is worn up to 5 days, is to reduce the physical and emotional symptoms of opioid withdrawal.
The Investigational Devic...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).